Issue 8   |  28 Feb 2022 


Study Overview
The TRACK trial will evaluate whether a small dose of rivaroxaban, a blood-thinning medication, would reduce cardiovascular death or major cardiovascular events in patients with advanced stages of chronic kidney disease.





TRACK Global Steering Committee Meeting
7.30pm (AEDT) | 2nd March 2022


Recruitment and Country Updates

To remain up to date on site status, visit

Figures are as of 28 Feb 2022. Only sites with participants on run-in or randomised have been included.



Important Study Updates


1. Tranche 1 On-Study Drug - Last Dispense Date

The last date of dispense for Tranche 1 on-study/maintenance drug (expiry of 1st September 2022) has been pushed further back to 1st of March 2022. This is to accommodate for the last few sites yet to receive Tranche 2 study drug. 

A reminder to sites to please monitor participants who are dispensed Tranche 1 maintenance bottles in February 2022 and ensure that these participants return for their subsequent dispense visit within 6 months.


2. Life-Threatening Assessment for SAEs/Outcomes

When reporting on SAEs and Outcomes in TRACK IBM database, please be mindful of the classification of 'Life-Threatening':

Life-Threatening in the definition of a Serious Adverse Event or Serious Adverse Reaction refers to an event in which the participant was at risk of death at the time of the event.


3. Rivaroxaban IB v29.0

The latest version of the Rivaroxaban Investigator's Brochure (version 29.0) has been released. This latest version includes updated information from on-going studies. Please note that there are no change to the risk/benefit assessment.


IBM Training Database Logins

For any site staff who wish to train/practice data entry for the study, please visit the TRACK Training IBM Database by logging in with any of the following updated training accounts.